| ||
| OXiGENE is Today's Focus Stock on MicroStockProfit.com TradersHuddle.com ZYBRESTAT, the Company's lead candidate, is being evaluated in studies of patients with anaplastic thyroid cancer (ATC), non-squamous non-small cell lung cancer and platinum-sensitive ovarian cancer. "Drug maker OXGN saw its stock rise over 7% in ... See all stories on this topic » | ||
| Celgene presents lung cancer trial data for Abraxane Zenopa Celgene has published new data from a phase III study evaluating its drug Abraxane as a therapy for advanced non-small cell lung cancer (NSCLC). During the study, the drug was combined with carboplatin and compared to a leading alternative, ... See all stories on this topic » | ||
| Lung Cancer Stage at Diagnosis: Individual Associations in the Prospective ... 7thSpace Interactive (press release) We used data from a prospective cohort study to evaluate associations of demographic, health history, and health behaviors with early versus late stage at diagnosis of non-small cell lung cancer (NSCLC). Methods: We calculated odds ratios (ORs) for the ... See all stories on this topic » | ||
| UT Southwestern Research Uncovers Genetic Link between Emphysema, Lung Cancer Newswise (press release) Although the new study showed PLAGL2 as a contributing factor in emphysema and lung cancer development, the diseases form in opposite ways. Emphysema arises from cell death or injury, while lung cancer involves uncontrolled cell growth. ... See all stories on this topic » | ||
| Positive Data on Roche's Tarceva Zacks.com The EURTAC trial was conducted in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). The trial results were presented at the 47th Annual Meeting of the American Society of Clinical Oncology. ... See all stories on this topic » | ||
| Merck plans cancer drug submissions later this year InPharm Merck had previously worked with Ariad on a co-development and co-commercialisation basis. The drug is being investigated in a number of different forms of the disease, including non-small cell lung cancer. See all stories on this topic » | ||
| Amrubicin Does Not Improve Overall Survival in SCLC Patients vs. Topotecan Monthly Prescribing Reference ... a third-generation anthracycline and topoisomerase II inhibitor, missed the primary endpoint of significantly improving overall survival (OS) over topotecan in the Phase 3 open-label ACT-1 trial to treat small cell lung cancer (SCLC), according to ... See all stories on this topic » | ||
| Fracking and Cell Phones: Evaluating the Real Risks TIME And if you're naturally skeptical about contradictory research that has been funded by the wireless companies — mobilemakers have been behind much of the research on their industry, just as the cigarette companies were decades ago on lung cancer ... See all stories on this topic » | ||
| Icotinib Provides Similar Efficacy, Better Tolerability Than Gefitinib in ... Monthly Prescribing Reference CHICAGO—A Phase 3 study demonstrated that icotinib provides comparable efficacy to oral gefitinib, but with a better safety profile, in patients with non-small cell lung cancer (NSCLC) who had progressed after one or two lines of therapy, according to ... See all stories on this topic » | ||
| In vitro Anti-angiogenic Properties of LGD1069, a Selective Retinoid X ... 7thSpace Interactive (press release) Our published study reported that LGD1069 inhibited tumor-induced angiogenesis in non-small cell lung cancer. In present study, we found that LGD1069 suppressed the proliferation, adhesion, invasion and migration of endothelial cells directly, ... See all stories on this topic » | ||
| Roche trial data shows Avastin's ovarian cancer benefits Zenopa ... including colorectal, breast, lung and kidney cancer. Earlier this week, the company also published new clinical trial data on another oncology agent, Tarceva, demonstrating its efficacy against advanced non-small cell lung cancer. See all stories on this topic » | ||
| 3 Stocks Shaking the Market Motley Fool With two cancer therapies ready to go to the next stage, drug developer Oncothyreon raised $43 million to fund their development. Stimuvax, a vaccine for patients with non-small cell lung cancer, is partnered with Germany's Merck KGaA, while PX-866, ... See all stories on this topic » | ||
| Piper Jaffray Maintains Overweight on Infinity Pharmaceuticals Benzinga In a note to clients, Piper Jaffray writes, "Infinity presented 2 posters on intravenous Heat Shock Protein-90 inhibitor retaspimycin including Phase Ib data in combination with Taxotere in non-small cell lung cancer at the American Society of Clinical ... See all stories on this topic » | ||
| US Markets Decline for Fourth Straight Session: S&P 500 Falls below 1300 Points USA Market News OXiGENE, Inc. (NASDAQ:OXGN) shares rose 7.5% after the business on Saturday accounted hopeful data on a possible remedy for non-small-cell lung cancer. Among the negative trend followers, Exelixis, Inc. (NASDAQ:EXEL) shares topple -0.20.20% after ... See all stories on this topic » | ||
| ||
| New Research Says XMRV Not Cause of CSF, Prostate Cancer Medscape "We detected XMRV infection in the two cell lines and in the later passage xenografts, but not in the early passages," the authors write. "For a retrovirus to cause cancer, almost every cancer cell should harbor the virus. When we found the virus was ... See all stories on this topic » |
| ||
| Positive Data On Roche's Tarceva By Zacks Investment Research The EURTAC trial was conducted in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). The trial results were presented at the 47th Annual Meeting of the American Society of Clinical Oncology ... DailyMarkets.com | ||
| Thalidomide for Malignant Pleural Mesothelioma After Induction ... A Phase 3 study demonstrated that icotinib provides comparable efficacy to oral gefitinib, but with a better safety profile, in patients with non-small cell lung cancer who had progressed after one or two lines of therapy, according to ... Latest articles from MPR | ||
| VEGF-C And VEGF-D Identified As Biomarkers For Avastin Resistance ... By Erica Teichert Avastin® is approved by the US FDA in the following indications: metastatic colorectal cancer, nonsquamous-cell lung cancer, metastatic breast cancer, glioblastoma, metastatic renal cell carcinoma. The VEGF-C inhibitor, VGX-100, ... Press Releases |
| ||
| D-Glucuronyl C5-epimerase suppresses small-cell lung cancer cell ... British Journal of Cancer advance online publication 7 June 2011; doi: 10.1038/ bjc.2011.170 E V Grigorieva 1 , 2 , T Y Prudnikova 1 , N V Domanitskaya 1 ... oneclick.indiatimes.com/article/0exGevbcpHeMj?q=Breast... | ||
| Older non-small cell lung cancer patients serum melatonin in ... In order to research the elderly non-small cell lung cancer patients serum melatonin in chemotherapy and change, we will according to the age of. treatments-for-lung-cancer.com/Older-non-small-cell-lung-can... | ||
| Optimization of Small-Cell Lung Cancer Chemotherapy with Heparin ... Purpose: In first-line management for small-cell lung cancer (SCLC), the combination of a platinum salt and etoposide is recommended, with thoracic ... content.karger.com/ProdukteDB/produkte.asp?Doi=328014 | ||
| All My brother has small cell lung cancer messages RE: My brother has small cell lung cancer. by thebyrdsfriend on Mon Jun 06, 2011 11:13 PM. Quote | Reply. She up-dated, you can read through the messages, ... https://www.cancercompass.com/message.../all,38239,0.htm?... |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment